Overview

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).

Features and Benefits of AVENIO ctDNA Expanded Kits

• Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
• Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques^2,3
• Includes reagents, bioinformatics and software
• Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
  

Product Highlights

Accurate detection of all four classes of mutations with high sensitivity and specificity^2,3

• >99% sensitivity for all four classes of mutations
• >99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs
  

View performance data showing >96 to >99% sensitivity and >98 to >99% PPV for all four classes of mutations using the AVENIO ctDNA Expanded Kit.

View the detailed gene list for the AVENIO Expanded Panel (part 1)

A portfolio of NGS liquid biopsy assays  

The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.